VABOMERE
Peakmeropenem-vaborbactam
NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
VABOMERE (meropenem-vaborbactam) is beta lactamase inhibitors [moa]. First approved in 2017.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VABOMERE is a fixed-dose combination of meropenem (a broad-spectrum beta-lactam antibiotic) and vaborbactam (a beta-lactamase inhibitor) administered intravenously. It is designed to treat complicated urinary tract infections and intra-abdominal infections caused by gram-negative bacteria resistant to standard carbapenems. The vaborbactam component protects meropenem from degradation by beta-lactamase enzymes, restoring its efficacy against resistant pathogens.
$0.002BPart D
Peak12.5 years to LOEProduct is at peak commercial performance with modest Part D penetration (~530 claims in 2023), suggesting stable but limited market adoption typical of specialty infectious disease agents.
Mechanism of Action
beta Lactamase Inhibitors
Pharmacologic Class:
beta Lactamase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Started Jul 2016
39 enrolled
Bacterial Infections
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Started Nov 2014
550 enrolled
Urinary Tract Infection ComplicatedAcute Pyelonephritis
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Started Jul 2014
77 enrolled
Urinary Tract Infection ComplicatedAcute PyelonephritisHospital Acquired Bacterial Pneumonia+3 more
Career Relevance
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.